Latest Safety News

Icetana Limited has successfully closed its renounceable pro rata entitlement offer, raising $629,422 through new share issuance, with convertible notes poised to convert into shares shortly.

Variscan Mines reports strong progress in its maiden underground drilling at the Udias Mine, with assay results expected soon, while advancing critical studies for a mine restart at its Novales-Udias Project.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

HyTerra Limited faces operational delays at its Nemaha Project due to severe winter weather but strengthens its management team with a key executive hire to drive 2025 exploration forward.

Artemis Resources has clarified the permitting status of its Radio Hill processing plant and outlined the regulatory and operational steps required to resume processing activities, while granting Greentech Metals an exclusive option to assess copper ore feasibility.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

White Cliff Minerals has awarded drilling contracts to Northspan Explorations for a 4,000-meter campaign at its Rae Copper Project in Nunavut, marking a significant exploration push after decades of dormancy.

Carbonxt Group Limited has initiated a $2 million Share Purchase Plan following successful capital raises, aiming to bolster its Kentucky activated carbon facility as it nears commercial production.

New Hope Group delivered a robust quarterly performance with a 21.8% rise in underlying EBITDA and a 33% jump in saleable coal production for the first half of FY25, underpinned by operational efficiencies and strategic investments.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Aurizon’s half-year FY2025 results reveal a 4% EBITDA decline despite a 6% increase in coal volumes, alongside mixed safety outcomes and an extended $300 million buy-back program.

Aurizon Holdings posted a 3% revenue increase to $2.02 billion for 1HFY2025 but saw EBITDA dip 4% to $814 million, reflecting operational headwinds across key segments. The company declared a 9.2 cents per share interim dividend, signaling cautious optimism despite margin pressures.